Indeed, at the transcriptional level, we confirmed that selected eIFs decrease in NAFLD patients compared to obese patients (eIF1, eIF4b, eIF3a), which can possibly be explained by a progressive decrease in the hepatic global translational rate during the worsening of hepatic steatosis to NAFLD [91]. The gene discussed is EIF3A; the disease is metabolic dysfunction-associated steatotic liver disease.